Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | CA7 | P43166 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 9/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134642 | 1.00 | CA1 (0.71) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL1414602 | 1.00 | CA1 (0.71) | CA1CA2CA7CYP2D6CA4 | |
| Carbamic Acid SCHEMBL15238275 | 0.93 | CA1 (0.63) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL38664436 | 0.87 | CA1 (0.69) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL15502138 | 0.87 | CA1 (0.59) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL9846504 | 0.87 | CA1 (0.59) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL12191653 | 0.87 | CA1 (0.59) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL15215102 | 0.87 | CA1 (0.59) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL9846502 | 0.87 | CA1 (0.59) | CA1CA2CA7CYP2D6CA4 | |
| SCHEMBL12739450 | 0.87 | CA1 (0.59) | CA1CA2CA7CYP2D6CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20250110407-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD, AND RESIST BASE FILM FORMING COMPOSITION | JSR CORPORATION (JP) | 2025-04-03 | — | — | US | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113166143-B | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods | 舒万诺知识产权公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20240105451-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION | JSR CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| US-20070244153-A1 | Diamine Derivative, Process of Preparation Thereof, and Fungicide Comprising Diamine Derivative as an Active Ingredient | MITSUI CHEMICALS, INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1770085-A1 | DIAMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND FUNGICIDE CONTAINING THE DERIVATIVE AS ACTIVE INGREDIENT | Mitsui Chemicals, Inc. (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-6696500-B2 | BIOACTIVE SUBSTANCE HAVING ACIDIC GROUP AND A BIODEGRADABLE POLYMER HAVING AN OPTIONALLY PROTECTED BASIC GROUP, SUCH AS A POLYLACTONE THAT HAS BEEN ESTERIFIED, AMIDATED, OR THIOESTERIFIED WITH A COMPOUND HAVING CYCLIC AMINO GROUPS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-1196409-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-04 | — | — | EP | disclosed |
| EP-0815853-B1 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20010038854-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6264970-B1 | BIODEGRADABLE POLYMER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-0815853-A2 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| CN-1130898-A | Difluorostone antiviral analogs | MERRELL DOW PHARMA (US) | 1996-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | CA1 477/4885CA2 309/4885CA7 160/4885 |
| US-20070244153-A1 | Diamine Derivative, Process of Preparation Thereof, and Fungicide Comprising Diamine Derivative as an Active Ingredient | DDT, AOC1, QDPR | CA1 1106/4885CA2 1140/4885CA7 1312/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | CA1 1674/4885CA2 3751/4885CA7 3282/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | CA1 2085/4885CA2 3450/4885CA7 2259/4885 |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | TUBB1, TUBB3, TUBB | CA1 4830/4885CA2 4396/4885CA7 4248/4885 |
| US-20010038854-A1 | Sustained-release preparation | BMP2, PGF, AREG | CA1 824/4885CA2 1351/4885CA7 1165/4885 |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, IRF3 | CA1 4661/4885CA2 4408/4885CA7 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.